first glp 1 approval Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1-based therapies for diabetes, obesity

Brain levels of glutamate, inhibitory transmitters -aminobutyric acid (GABA) and N-acetylaspartylglutamate (NAAG), and myoinositol (MI), an osmolyte linked to Alzheimers disease in humans, were measured in three 2 2 2-cm 3 left-sided brain regions (dorsolateral frontal, posterior cingulate, and posterior parietal)

10.1111/bjh.12643 103

Efficacy Results by Sex, Race, Age, and Ethnicity, Efficacy Population Source: Adapted from FDA Review 1 Event refers to the CAC-adjudicated CRBSI

Several recent CVOTs have shown that GLP-1RAs can reduce the decline of estimated GFR (eGFR) and delay the onset of the occurrence of proteinuria in patients with T2DM [4, 22, 26, 46, 47]